Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

This study has been completed.
Information provided by:
Teva Pharmaceutical Industries Identifier:
First received: September 30, 2003
Last updated: May 8, 2014
Last verified: May 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2007
  Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)